# WIA-AUG-002: Cybernetic Implant Specification v1.0

> **Standard ID:** WIA-AUG-002
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Human Augmentation Cybernetics Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Implant Classification System](#2-implant-classification-system)
3. [Biocompatibility Framework](#3-biocompatibility-framework)
4. [Power Management](#4-power-management)
5. [Communication Protocols](#5-communication-protocols)
6. [Surgical Integration](#6-surgical-integration)
7. [Rejection Monitoring](#7-rejection-monitoring)
8. [Firmware Update Protocols](#8-firmware-update-protocols)
9. [End-of-Life Procedures](#9-end-of-life-procedures)
10. [Implementation Guidelines](#10-implementation-guidelines)
11. [References](#11-references)

---

## 1. Introduction

### 1.1 Purpose

This specification defines comprehensive standards for cybernetic implants, covering classification, biocompatibility, power management, communication, surgical integration, monitoring, firmware updates, and end-of-life management.

### 1.2 Scope

The standard covers:
- Classification of implant types and capabilities
- Biocompatibility requirements and testing
- Power source selection and management
- Internal and external communication protocols
- Surgical implantation and integration procedures
- Real-time rejection monitoring systems
- Safe firmware update mechanisms
- Explantation and disposal procedures

### 1.3 Philosophy

**弘益人間 (Benefit All Humanity)** - Cybernetic implants represent the fusion of human biology and technology. This standard ensures that such devices enhance human capabilities safely, ethically, and effectively while respecting human dignity and autonomy.

### 1.4 Terminology

- **Cybernetic Implant**: A device surgically placed within the human body that interfaces with biological systems
- **Biocompatibility**: The ability of a material to perform without adverse biological response
- **Integration**: The process of biological tissue accepting and incorporating an implant
- **Rejection**: Immune system response leading to implant failure or removal
- **Osseointegration**: Direct structural connection between bone and implant
- **Neural Interface**: Connection between implant electronics and neural tissue

---

## 2. Implant Classification System

### 2.1 Classification by Type

Implants are classified into four primary types:

| Type | Description | Power | Intelligence | Neural Connection |
|------|-------------|-------|--------------|-------------------|
| PASSIVE | Mechanical function only | None | None | No |
| ACTIVE | Basic electronic function | Battery | Limited | Optional |
| SMART | Advanced processing | Battery/Hybrid | AI-enabled | Optional |
| NEURAL_INTERFACE | Direct neural control | Hybrid | Advanced AI | Required |

### 2.2 Classification Algorithm

```typescript
interface ImplantClassificationInput {
  hasPowerSource: boolean;
  hasProcessing: boolean;
  hasNeuralConnection: boolean;
  adaptiveBehavior: boolean;
  aiCapability: boolean;
}

function classifyImplantType(input: ImplantClassificationInput): ImplantType {
  if (!input.hasPowerSource) return 'PASSIVE';
  if (!input.hasProcessing) return 'ACTIVE';
  if (!input.hasNeuralConnection && !input.aiCapability) return 'ACTIVE';
  if (input.hasNeuralConnection) return 'NEURAL_INTERFACE';
  if (input.adaptiveBehavior || input.aiCapability) return 'SMART';
  return 'ACTIVE';
}
```

### 2.3 Classification by Integration Level

```
Level 1: Subcutaneous (under skin, above muscle)
Level 2: Muscular (within muscle tissue)
Level 3: Osseous (integrated with bone)
Level 4: Neural (connected to peripheral nerves)
Level 5: Cognitive (integrated with brain/CNS)
```

### 2.4 Integration Level Requirements

| Level | Surgical Complexity | Recovery Time | Biocompatibility | Monitoring |
|-------|-------------------|---------------|------------------|------------|
| 1 | Low | 1-2 weeks | Class I/II | Monthly |
| 2 | Moderate | 2-4 weeks | Class II | Bi-weekly |
| 3 | High | 6-12 weeks | Class III | Weekly |
| 4 | Very High | 3-6 months | Class III | Continuous |
| 5 | Critical | 6-12 months | Class III | Real-time |

---

## 3. Biocompatibility Framework

### 3.1 Biocompatibility Classes

```
Class I: Surface Contact
  - Duration: < 24 hours
  - Location: External or brief internal
  - Testing: ISO 10993-5 (Cytotoxicity)

Class II: Limited Duration
  - Duration: < 30 days
  - Location: Internal, non-permanent
  - Testing: ISO 10993-5, 10, 11

Class III: Permanent Implant
  - Duration: > 30 days (lifetime)
  - Location: Deep tissue, bone, neural
  - Testing: Full ISO 10993 suite
```

### 3.2 Material Requirements

#### 3.2.1 Approved Materials

| Material | Properties | Applications | Class |
|----------|-----------|--------------|-------|
| Titanium (Ti6Al4V) | High strength, inert | Structural, bone | III |
| Medical-grade Silicone | Flexible, bioactive | Soft tissue | II, III |
| PEEK (Polyether ether ketone) | Strong, radiolucent | Structural | III |
| Platinum-Iridium | Conductive, stable | Electrodes | III |
| Parylene C | Thin, conformal | Coating | III |
| Hydrogel | Soft, permeable | Interface | II, III |

#### 3.2.2 Material Testing Requirements

```json
{
  "class_I": {
    "required_tests": [
      "cytotoxicity"
    ]
  },
  "class_II": {
    "required_tests": [
      "cytotoxicity",
      "sensitization",
      "irritation",
      "systemic_toxicity"
    ]
  },
  "class_III": {
    "required_tests": [
      "cytotoxicity",
      "sensitization",
      "irritation",
      "systemic_toxicity",
      "genotoxicity",
      "implantation",
      "hemocompatibility",
      "carcinogenicity",
      "reproductive_toxicity"
    ]
  }
}
```

### 3.3 Biocompatibility Assessment

```typescript
interface BiocompatibilityAssessment {
  implantId: string;
  materialComposition: string[];
  bioClass: 'CLASS_I' | 'CLASS_II' | 'CLASS_III';
  contactDuration: 'limited' | 'prolonged' | 'permanent';
  tissueType: 'skin' | 'muscle' | 'bone' | 'blood' | 'neural';
  testResults: {
    test: string;
    standard: string;
    result: 'PASS' | 'FAIL' | 'PENDING';
    date: Date;
    lab: string;
  }[];
  compliant: boolean;
}
```

---

## 4. Power Management

### 4.1 Power Source Types

#### 4.1.1 Battery Power

```
Type: Rechargeable Lithium-Ion or Lithium-Polymer
Capacity: 100-5000 mAh (application-dependent)
Voltage: 3.0-4.2V nominal
Charging: Wireless inductive or conductive
Lifetime: 5-10 years (500-1000 cycles)
Safety: Overcharge/overdischarge protection
```

#### 4.1.2 Wireless Power Transfer

```
Near-Field (Inductive):
  - Frequency: 13.56 MHz or 6.78 MHz
  - Range: 0-10 cm
  - Efficiency: 60-80%
  - Power: 1-50W

Far-Field (RF):
  - Frequency: 2.4 GHz or 5.8 GHz
  - Range: 10-100 cm
  - Efficiency: 10-30%
  - Power: 0.1-5W
```

#### 4.1.3 Bio-Harvesting

```
Kinetic Energy:
  - Source: Body movement, muscle contraction
  - Power: 10-500 μW
  - Mechanism: Piezoelectric, electromagnetic

Thermal Energy:
  - Source: Body heat gradient
  - Power: 1-100 μW
  - Mechanism: Thermoelectric generator

Biochemical Energy:
  - Source: Glucose in blood/interstitial fluid
  - Power: 1-1000 μW
  - Mechanism: Enzymatic fuel cell
```

#### 4.1.4 Hybrid Systems

```
Configuration:
  - Primary: Battery or wireless
  - Secondary: Bio-harvesting
  - Tertiary: Capacitor backup

Power Management:
  - Intelligent source switching
  - Load balancing
  - Priority-based allocation
  - Fail-safe modes
```

### 4.2 Power Management Protocol

```typescript
interface PowerManagementConfig {
  primarySource: PowerSource;
  backupSources: PowerSource[];
  chargingSchedule: {
    frequency: 'daily' | 'weekly' | 'monthly' | 'continuous';
    duration: number; // minutes
    method: 'inductive' | 'rf' | 'wired';
  };
  lowPowerThreshold: number; // percentage
  criticalPowerThreshold: number; // percentage
  safeModeConfig: {
    trigger: number; // percentage
    reducedFunctions: string[];
    essentialFunctions: string[];
  };
}
```

### 4.3 Power Monitoring

```
Metrics:
  - Battery level (0-100%)
  - Charge cycles count
  - Power consumption (mW)
  - Estimated runtime (hours)
  - Charging status
  - Source availability

Alerts:
  - Low power warning (< 20%)
  - Critical power alert (< 5%)
  - Charging required
  - Source failure
  - Abnormal consumption
```

---

## 5. Communication Protocols

### 5.1 Internal Communication

#### 5.1.1 Neural Interface Protocol

```
Signal Type: Bioelectrical potentials
Frequency Range: 0.1 Hz - 10 kHz
Sampling Rate: 1-50 kHz
Channels: 1-256 (array-dependent)
Impedance: < 1 MΩ @ 1 kHz
Encoding: Spike detection, frequency modulation
Processing: Real-time digital signal processing
```

#### 5.1.2 Implant-to-Implant Communication

```
Protocol: Medical Body Area Network (MBAN)
Frequency: 2.4 GHz ISM band
Range: 0-2 meters (in-body)
Data Rate: 1 Mbps
Topology: Mesh or star
Security: AES-256 encryption
Power: Ultra-low (< 10 mW)
```

### 5.2 External Communication

#### 5.2.1 Bluetooth Low Energy (BLE)

```
Version: BLE 5.0+
Frequency: 2.4 GHz
Range: 0-10 meters
Data Rate: 125 kbps - 2 Mbps
Power: < 15 mW
Use Cases: Mobile apps, configuration, data sync
Security: Pairing, bonding, encryption
```

#### 5.2.2 Medical Implant Communication Service (MICS)

```
Frequency: 402-405 MHz
Range: 0-2 meters
Data Rate: 200-800 kbps
Power: < 25 μW
Use Cases: Clinical monitoring, diagnostics
Regulation: FCC Part 95 (USA), ETSI EN 301 839 (EU)
```

#### 5.2.3 Near-Field Communication (NFC)

```
Frequency: 13.56 MHz
Range: 0-10 cm
Data Rate: 106-424 kbps
Power: Passive (reader-powered)
Use Cases: ID, configuration, emergency access
Standard: ISO/IEC 14443, 15693
```

### 5.3 Communication Security

```
Requirements:
  - End-to-end encryption (AES-256)
  - Mutual authentication
  - Secure key exchange
  - Anti-replay protection
  - Access control (role-based)
  - Audit logging

Privacy:
  - Data anonymization
  - Patient consent management
  - HIPAA/GDPR compliance
  - Secure data storage
  - Right to erasure
```

---

## 6. Surgical Integration

### 6.1 Pre-Operative Assessment

#### 6.1.1 Patient Screening

```
Medical History:
  - Previous surgeries
  - Allergies and sensitivities
  - Medications
  - Immune status
  - Comorbidities

Physical Examination:
  - Implant site assessment
  - Tissue quality
  - Vascular mapping
  - Neural mapping (if applicable)

Diagnostic Tests:
  - Blood work (CBC, metabolic panel)
  - Imaging (CT, MRI, ultrasound)
  - Biocompatibility patch test
  - Psychological evaluation (Level 4-5)
```

#### 6.1.2 Implant Site Selection

```
Criteria:
  - Anatomical suitability
  - Tissue thickness and quality
  - Proximity to nerves/vessels
  - Mobility considerations
  - Patient lifestyle
  - Aesthetic considerations

Planning:
  - 3D modeling and simulation
  - Surgical approach planning
  - Backup site identification
  - Risk assessment
```

### 6.2 Intra-Operative Procedure

#### 6.2.1 Standard Surgical Protocol

```
Phase 1: Preparation
  - Anesthesia (local/regional/general)
  - Sterile field preparation
  - Patient positioning
  - Equipment verification

Phase 2: Implantation
  - Incision and tissue exposure
  - Pocket creation or bone preparation
  - Implant positioning and fixation
  - Neural connection (if applicable)
  - Vascular considerations

Phase 3: Activation
  - Power system activation
  - Communication link establishment
  - Functional testing
  - Calibration and tuning

Phase 4: Closure
  - Hemostasis verification
  - Layered closure
  - Dressing application
  - Post-op imaging
```

#### 6.2.2 Neural Interface Integration

```
Procedure:
  1. Nerve identification and exposure
  2. Epineurial window creation
  3. Electrode array insertion
  4. Fixation and anchoring
  5. Electrical testing
  6. Signal quality verification
  7. Threshold mapping
  8. Protective wrapping

Monitoring:
  - Impedance measurement
  - Signal-to-noise ratio
  - Stimulation thresholds
  - Evoked potentials
  - No adverse neural response
```

### 6.3 Post-Operative Care

#### 6.3.1 Acute Phase (0-2 weeks)

```
Monitoring:
  - Wound healing
  - Pain management
  - Infection surveillance
  - Device function
  - Early rejection signs

Actions:
  - Dressing changes
  - Antibiotic prophylaxis
  - Pain medication
  - Limited activity
  - Daily device checks
```

#### 6.3.2 Integration Phase (2 weeks - 6 months)

```
Monitoring:
  - Tissue integration progress
  - Impedance changes
  - Functional improvement
  - Rejection markers
  - Patient adaptation

Actions:
  - Progressive rehabilitation
  - Calibration adjustments
  - Training sessions
  - Psychological support
  - Bi-weekly clinical visits
```

#### 6.3.3 Maintenance Phase (6+ months)

```
Monitoring:
  - Long-term stability
  - Performance metrics
  - Wear and aging
  - Patient satisfaction
  - Lifestyle integration

Actions:
  - Monthly/quarterly checkups
  - Software updates
  - Optimization
  - Preventive maintenance
  - Continuous education
```

---

## 7. Rejection Monitoring

### 7.1 Rejection Mechanisms

```
Types of Rejection:
  1. Acute Rejection (0-3 months)
     - Rapid immune response
     - Inflammation, pain, swelling
     - High severity

  2. Chronic Rejection (3+ months)
     - Slow tissue degradation
     - Encapsulation, fibrosis
     - Progressive dysfunction

  3. Infection-Related
     - Bacterial biofilm
     - Systemic infection
     - Secondary rejection
```

### 7.2 Biomarker Monitoring

#### 7.2.1 Inflammatory Markers

```
C-Reactive Protein (CRP):
  - Normal: < 3 mg/L
  - Warning: 3-10 mg/L
  - Critical: > 10 mg/L
  - Measurement: Blood test

Interleukin-6 (IL-6):
  - Normal: < 5 pg/mL
  - Warning: 5-20 pg/mL
  - Critical: > 20 pg/mL
  - Measurement: Blood test

Local Temperature:
  - Normal: 36-37°C
  - Warning: 37-38°C
  - Critical: > 38°C
  - Measurement: Implant sensor
```

#### 7.2.2 Immune Response Markers

```
Antibody Levels:
  - IgG, IgM against implant materials
  - Normal: < 100 AU/mL
  - Warning: 100-500 AU/mL
  - Critical: > 500 AU/mL

T-Cell Activation:
  - CD4+, CD8+ counts
  - Normal: Baseline ± 20%
  - Warning: Baseline ± 20-50%
  - Critical: > 50% deviation

Complement Activation:
  - C3a, C5a levels
  - Normal: < 200 ng/mL
  - Warning: 200-1000 ng/mL
  - Critical: > 1000 ng/mL
```

#### 7.2.3 Tissue Integrity Markers

```
Impedance (Neural Implants):
  - Normal: 100-500 kΩ
  - Warning: 500 kΩ - 1 MΩ
  - Critical: > 1 MΩ or < 50 kΩ

Signal Quality:
  - Normal: SNR > 10 dB
  - Warning: SNR 5-10 dB
  - Critical: SNR < 5 dB

Tissue Edema:
  - Ultrasound thickness measurement
  - Normal: Baseline ± 10%
  - Warning: Baseline ± 10-30%
  - Critical: > 30% increase
```

### 7.3 Monitoring Protocol

```typescript
interface RejectionMonitoringData {
  timestamp: Date;
  implantId: string;
  biomarkers: {
    crp: number;          // mg/L
    il6: number;          // pg/mL
    temperature: number;  // Celsius
    antibodies: number;   // AU/mL
    tcells: number;       // % deviation
    impedance: number;    // kΩ
    signalQuality: number; // SNR dB
  };
  clinicalSigns: {
    pain: number;         // 0-10 scale
    swelling: boolean;
    redness: boolean;
    warmth: boolean;
    discharge: boolean;
  };
  deviceMetrics: {
    functionality: number; // 0-100%
    powerConsumption: number; // mW
    communicationQuality: number; // 0-100%
  };
}
```

### 7.4 Rejection Response Protocol

```
Level 1 (Green - Normal):
  - All parameters within normal range
  - Action: Continue routine monitoring

Level 2 (Yellow - Warning):
  - 1-2 parameters in warning range
  - Action: Increase monitoring frequency
  - Clinical assessment within 1 week

Level 3 (Orange - Concern):
  - 3+ parameters in warning or 1 in critical
  - Action: Immediate clinical evaluation
  - Enhanced monitoring (daily)
  - Consider intervention

Level 4 (Red - Critical):
  - Multiple critical parameters
  - Action: Emergency medical intervention
  - Possible explantation
  - Intensive treatment
```

---

## 8. Firmware Update Protocols

### 8.1 Update Classification

```
Type 1: Critical Security Update
  - Urgency: Immediate (0-24 hours)
  - Mandatory: Yes
  - Risk: High if not applied
  - Approval: Automatic

Type 2: Safety Patch
  - Urgency: Scheduled (1-7 days)
  - Mandatory: Yes
  - Risk: Moderate if not applied
  - Approval: User notification

Type 3: Feature Update
  - Urgency: Elective
  - Mandatory: No
  - Risk: Low
  - Approval: User consent

Type 4: Performance Optimization
  - Urgency: Recommended
  - Mandatory: No
  - Risk: None
  - Approval: User consent
```

### 8.2 Update Process

#### 8.2.1 Pre-Update Phase

```
Steps:
  1. Health check verification
     - Battery level > 50%
     - No active alerts
     - Communication stable
     - Tissue integration normal

  2. Configuration backup
     - Settings export
     - Calibration data
     - User preferences
     - Event logs

  3. Update preparation
     - Download firmware
     - Verify signature
     - Check compatibility
     - Allocate resources
```

#### 8.2.2 Update Phase

```
Steps:
  1. Enter safe mode
     - Reduce functions
     - Maintain vital operations
     - Enable monitoring
     - Alert user

  2. Apply update
     - Flash new firmware
     - Verify integrity
     - Update checksum
     - Test critical functions

  3. Post-update verification
     - Boot new firmware
     - Self-test sequence
     - Restore configuration
     - Validate functionality
```

#### 8.2.3 Post-Update Phase

```
Steps:
  1. Resume normal operation
     - Exit safe mode
     - Restore full functions
     - Recalibrate as needed
     - Clear safe mode flags

  2. Extended monitoring (24-72 hours)
     - Enhanced logging
     - Performance tracking
     - Error detection
     - User feedback

  3. Rollback capability
     - Previous firmware retained
     - Rollback within 48 hours
     - Triggered by failures
     - Automatic or manual
```

### 8.3 Update Security

```
Requirements:
  - Code signing (PKI)
  - Encrypted transmission
  - Version verification
  - Rollback protection
  - Secure boot

Verification:
  - Digital signature check
  - Hash verification (SHA-256)
  - Manufacturer certificate
  - Anti-downgrade protection
  - Authenticity confirmation
```

### 8.4 Professional Supervision

```
Level 1-2 Implants:
  - Over-the-air updates allowed
  - User-initiated
  - Remote monitoring

Level 3 Implants:
  - OTA allowed with notification
  - Medical professional informed
  - Remote clinical monitoring

Level 4-5 Implants:
  - Clinical setting required
  - Medical supervision mandatory
  - Real-time monitoring
  - Emergency protocols active
```

---

## 9. End-of-Life Procedures

### 9.1 Explantation Triggers

```
Category A: Device Failure
  - Complete malfunction
  - Safety hazard
  - Unrecoverable error
  - Urgency: Emergency

Category B: Medical Necessity
  - Severe rejection
  - Infection
  - Tissue damage
  - Urgency: Urgent

Category C: Upgrade
  - Better technology available
  - Enhanced capabilities
  - Patient choice
  - Urgency: Elective

Category D: End of Service Life
  - Planned replacement
  - Battery depletion
  - Component wear
  - Urgency: Scheduled
```

### 9.2 Explantation Planning

#### 9.2.1 Pre-Operative Assessment

```
Medical Evaluation:
  - Current health status
  - Tissue condition
  - Integration assessment
  - Risk stratification

Surgical Planning:
  - Approach determination
  - Tissue preservation strategy
  - Complication anticipation
  - Replacement consideration

Patient Preparation:
  - Informed consent
  - Expectation management
  - Recovery planning
  - Psychological support
```

#### 9.2.2 Explantation Procedure

```
Phase 1: Device Deactivation
  - Power down
  - Data extraction
  - Communication cessation
  - Safe mode activation

Phase 2: Surgical Removal
  - Tissue dissection
  - Implant extraction
  - Minimal tissue damage
  - Hemostasis

Phase 3: Site Management
  - Tissue repair
  - Void filling (if needed)
  - Infection prevention
  - Closure

Phase 4: Recovery
  - Wound healing
  - Function restoration
  - Rehabilitation
  - Follow-up care
```

### 9.3 Device Disposal

#### 9.3.1 Data Sanitization

```
Process:
  1. Data extraction (if needed)
     - Patient logs
     - Performance data
     - Medical records
     - Research data

  2. Secure erasure
     - Multi-pass overwrite
     - Cryptographic erasure
     - Physical destruction (if needed)
     - Verification

  3. Privacy compliance
     - HIPAA requirements
     - GDPR rights
     - Patient consent
     - Documentation
```

#### 9.3.2 Material Recycling

```
Metals (Titanium, Platinum):
  - Sterilization
  - Material recovery
  - Refining
  - Certification

Electronics:
  - Component separation
  - E-waste processing
  - Hazardous material handling
  - Environmental compliance

Biological Materials:
  - Medical waste protocols
  - Autoclaving/incineration
  - Proper disposal
  - Regulatory compliance
```

### 9.4 Registry Update

```
Documentation:
  - Explantation record
  - Reason for removal
  - Device condition
  - Patient outcome
  - Lessons learned

Registry Notification:
  - Manufacturer notification
  - FDA/regulatory reporting
  - Medical device registry
  - Research database
  - Quality improvement
```

---

## 10. Implementation Guidelines

### 10.1 Certification Requirements

To achieve WIA-AUG-002 certification:

```
1. Implant Classification
   - Type determination (PASSIVE/ACTIVE/SMART/NEURAL_INTERFACE)
   - Integration level assignment
   - Risk assessment

2. Biocompatibility Certification
   - Material testing (ISO 10993)
   - Class determination
   - Test reports

3. Power Management Validation
   - Power source qualification
   - Battery safety testing
   - Charging system validation
   - Fail-safe verification

4. Communication Compliance
   - Protocol implementation
   - Security validation
   - Regulatory compliance (FCC, CE)
   - Interoperability testing

5. Surgical Protocol Development
   - Procedure documentation
   - Training materials
   - Complication management
   - Success criteria

6. Monitoring System Implementation
   - Biomarker tracking
   - Alert system
   - Data management
   - Clinical integration

7. Firmware Update System
   - Secure update mechanism
   - Rollback capability
   - Testing and validation
   - Safety verification

8. End-of-Life Planning
   - Explantation protocol
   - Disposal procedures
   - Data management
   - Registry compliance
```

### 10.2 Documentation Requirements

```
Required Documents:
□ Device Master File
□ Classification Report
□ Biocompatibility Test Reports
□ Power System Validation
□ Communication Protocol Specification
□ Surgical Manual
□ Rejection Monitoring Protocol
□ Firmware Update Procedure
□ Explantation Guide
□ Risk Management File (ISO 14971)
□ Clinical Evaluation Report
□ Post-Market Surveillance Plan
□ User Manual
□ Training Materials
□ Quality Management System (ISO 13485)
```

### 10.3 API Interface

```typescript
// Implant Management API
interface ImplantAPI {
  // Classification
  classifyImplant(input: ClassificationInput): Classification;

  // Biocompatibility
  assessBiocompatibility(params: BioAssessmentParams): BiocompatibilityResult;

  // Power Management
  configurePower(config: PowerConfig): PowerStatus;
  monitorPower(): PowerMetrics;

  // Communication
  establishConnection(protocol: CommProtocol): Connection;
  sendData(data: ImplantData): TransmissionResult;

  // Monitoring
  monitorRejection(implantId: string): RejectionStatus;
  getVitals(): VitalMetrics;

  // Firmware
  checkUpdates(): UpdateInfo;
  applyUpdate(updateId: string): UpdateResult;
  rollback(): RollbackResult;

  // Lifecycle
  scheduleExplant(params: ExplantParams): ExplantSchedule;
  deactivateImplant(): DeactivationResult;
}
```

### 10.4 Testing Requirements

```
Pre-Clinical Testing:
  - Mechanical testing (fatigue, stress)
  - Electrical testing (leakage, isolation)
  - Biocompatibility testing
  - Animal studies (if required)
  - Aging and stability

Clinical Testing:
  - Phase I: Safety (10-30 subjects)
  - Phase II: Efficacy (50-100 subjects)
  - Phase III: Large-scale (200-1000 subjects)
  - Long-term follow-up (5-10 years)

Post-Market Surveillance:
  - Adverse event reporting
  - Performance monitoring
  - Registry participation
  - Continuous improvement
```

---

## 11. References

### 11.1 International Standards

1. **ISO 10993** - Biological evaluation of medical devices
2. **ISO 14971** - Medical devices — Application of risk management
3. **IEC 60601-1** - Medical electrical equipment — General requirements
4. **IEC 60601-1-2** - EMC requirements for medical devices
5. **IEC 62304** - Medical device software — Software life cycle processes
6. **ISO 13485** - Medical devices — Quality management systems
7. **IEEE 802.15.6** - Wireless Body Area Networks (WBAN)
8. **ISO 11737** - Sterilization of medical devices

### 11.2 Regulatory Guidelines

- **FDA Guidance**: Implantable Medical Devices
- **EU MDR 2017/745** - Medical Device Regulation
- **FCC Part 95** - Medical Implant Communications Service
- **HIPAA** - Health Insurance Portability and Accountability Act
- **GDPR** - General Data Protection Regulation

### 11.3 WIA Standards

- **WIA-AUG-001**: Human Augmentation General Standards
- **WIA-AUG-013**: Augmentation Safety
- **WIA-AUG-014**: Human-Machine Interface
- **WIA-BCI**: Brain-Computer Interface Standards
- **WIA-SEC**: Security Standards for Medical Devices
- **WIA-MED**: Medical Device Standards

### 11.4 Scientific References

1. Williams, D.F. (2008). "On the mechanisms of biocompatibility." *Biomaterials*, 29(20), 2941-2953.
2. 선행 연구. "A critical review of interfaces with the peripheral nervous system." *Journal of the Peripheral Nervous System*, 10(3), 229-258.
3. Pancrazio, J.J., Peckham, P.H. (2009). "Neuroprosthetic devices: how far are we from recovering movement in paralyzed patients?" *Expert Review of Neurotherapeutics*, 9(4), 427-430.

---

## Appendix A: Implant Classification Worksheet

```
Device Name: _______________
Manufacturer: _______________
Date: _______________

Classification Criteria:
□ Power Source: None / Battery / Wireless / Bio-harvest / Hybrid
□ Processing: None / Basic / Advanced / AI
□ Neural Connection: No / Peripheral / Central
□ Adaptive Behavior: No / Yes
□ AI Capability: No / Yes

Determined Type: _______________ (PASSIVE/ACTIVE/SMART/NEURAL_INTERFACE)

Integration Level:
□ Anatomical Location: _______________
□ Tissue Type: Skin / Muscle / Bone / Neural
□ Depth: Level ___ (1-5)

Biocompatibility Class:
□ Contact Duration: Limited / Prolonged / Permanent
□ Tissue Contact: _______________
□ Class: I / II / III

Risk Assessment:
□ Overall Risk: Low / Moderate / High / Critical
□ Special Considerations: _______________
```

## Appendix B: Rejection Monitoring Checklist

```
Implant ID: _______________
Date: _______________
Assessor: _______________

Biomarkers:
□ CRP: ___ mg/L (Normal < 3, Warning 3-10, Critical > 10)
□ IL-6: ___ pg/mL (Normal < 5, Warning 5-20, Critical > 20)
□ Temperature: ___ °C (Normal 36-37, Warning 37-38, Critical > 38)
□ Antibodies: ___ AU/mL (Normal < 100, Warning 100-500, Critical > 500)
□ Impedance: ___ kΩ (Normal 100-500, Warning 500-1000, Critical > 1000)

Clinical Signs:
□ Pain: ___/10
□ Swelling: No / Yes
□ Redness: No / Yes
□ Warmth: No / Yes
□ Discharge: No / Yes

Overall Assessment:
□ Level 1 (Green - Normal)
□ Level 2 (Yellow - Warning)
□ Level 3 (Orange - Concern)
□ Level 4 (Red - Critical)

Action Required: _______________
```

---

**弘益人間 (홍익인간) · Benefit All Humanity**

*WIA-AUG-002 Specification v1.0*
*© 2025 SmileStory Inc. / WIA*
*MIT License*
